Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Eden vs Navio MD

Both scored on the same six-factor Match Score. Eden wins this matchup with a 87 to 74 edge.

Higher Match Score

Eden

#7 · Grade B+

People who prioritize a vetted, high-transparency, high-touch provider over the lowest sticker price.

Visit Eden
VS

Navio MD

#72 · Grade C

People who want compounded tirzepatide with brand-name fallback across 48 states.

Visit Navio MD

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
74
55
Speed to Start
90
83
Formulary Match
80
79
Support Level
94
83
Flexibility
90
55
Transparency
92
94

Price, coverage & formulary

DetailEdenNavio MD
Semaglutide$239/mo$345/mo (starting dose, brand-name)
Tirzepatide$349/mo$189/mo (starting dose, compounded)
CoverageAll 50 states48 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjectable onlyInjectable only
Match Score87 · B+74 · C
Winner: Eden

Eden edges out Navio MD, 87 to 74 on the default Match Score. A polished, high-disclosure compounded program with strong nationwide coverage and hands-on support.

Navio MD is still a fair pick if its strengths line up with yours — best for: People who want compounded tirzepatide with brand-name fallback across 48 states.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Eden reviewFull Navio MD review

More head-to-heads

Or browse alternatives to Eden and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.